FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvasimigion, D.C. 20040

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average bu	rden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Babu Yarlagadda S						2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX]								neck all applic Directo V Officer	ationship of Reporting all applicable) Director Officer (give title below)		10% Ow Other (s	ner	
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 01/01/2015								Senior VP - Drug Discovery					
(Street) DURHAM NC 27703 (City) (State) (Zip)					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								e) X Form f Form f	lividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Ta	ble I - Noi	n-Deri	vativ	re Se	ecurities	Aco	uired,	Dis	posed of	, or Ben	eficial	ly Owned					
1. Title of Security (Instr. 3) 2. Trai					nsaction n/Day/Year)		2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities Acquired (A)			5. Amou Securitie Benefici Owned F	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	ion(s)			Instr. 4)	
Common Stock 01/01/						2015		A		8,900(1) A	\$0	217	,095		D			
Common Stock 01/01/						/2015		F		2,402(2) D	\$12.	16 214	1,693	D				
			Table II -								osed of, convertib			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	ate, T	Code (Instr.				6. Date Exercisable Expiration Date (Month/Day/Year)		te	of Securities		Derivative Security	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	V	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(a)			
Emp. Stock Option (Right to Buy)	\$12.16	01/01/2015			A		42,400 ⁽³⁾		01/01/20	016	01/01/2025	Common Stock	42,400	\$0	42,40	00	D		

Explanation of Responses:

- 1. Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- 2. Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013.
- 3. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of attorney 01/05/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.